This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Mikey Czech Foundation Contributes $500,000 To DIPG Research At Dana-Farber Cancer Institute - Harvard Medical School

NEW CANAAN, Conn., April 2, 2013 /PRNewswire/ -- The Mikey Czech Foundation, Inc. (the "Foundation", www.mikeyczech.org) a 501 (c)(3) non-profit foundation established by the Stephen J. Czech family to finance medical research for pediatric brain tumors, announced a $500,000 gift to the Dana-Farber Cancer Institute's Pediatric Neuro-Oncology Center, headed by Dr. Mark W. Kieran, MD, PhD, and located in Boston, Massachusetts. The proceeds of the gift are designed to further the research and development of remedies for Diffuse Intrinsic Pontine Glioma ("DIPG") pediatric brain tumors, the type of tumor that claimed the life of James Michael "Mikey" Czech in 2008 at age 11.

DIPG brain stem tumors affect the cranial nerves of children, ages 3 – 16 years old, destroying the nerves that supply the muscles of the eye and face, and muscles involved in swallowing. Symptoms include double vision, inability to close the eyelids completely, "drooping" on one side of the face, and difficulty chewing and swallowing. The tumor also affects the "long tracks" of the brain, with resultant weakness of the arms or legs and difficulty with speech and walking. As the tumor grows, children initially lose their ability to use their limbs. Thereafter, they sequentially lose control of their bowels, hearing, vision and their ability to swallow and breathe. Notwithstanding their physical deterioration, the children maintain their mental faculties, are fully cognizant of what is happening to them, and experience pain comparable to that of being skinned alive. Survival past 12 to 14 months is uncommon, and new approaches to treating these tumors are urgently needed as no remedies currently exist to treat DIPGs.

"The assets required to cure DIPGs consist of: (a) a sustainable funding source; (b) world-class neuro-oncologists; and (c) state-of-the-art research facilities," said Steve Czech, Mikey's father and Chairman & Co-Founder of The Mikey Czech Foundation. "We intend to be the sustainable funding source and we believe that Dr. Kieran, his colleagues and Dana-Farber represent the 'best-in-class' with respect to pediatric neuro-oncology research and state-of-the-art research facilities. It is our hope that this gift will be the first in a series of gifts, comparable or larger in size, designed to eradicate this heinous disease."

In addition to his efforts with the Foundation, Czech is the Managing Partner and Chief Investment Officer of Czech Asset Management, L.P., a credit focused alternative investment manager based in Greenwich, CT. In an effort to establish a sustainable funding source for DIPG research, Czech contributes a percentage of his investment profits each year to DIPG research.

"Funding from The Mikey Czech Foundation is critical because it will allow us to conduct research to define the underlying molecular changes in DIPG that have previously made these tumors so resistant to therapy," said Dr. Mark W. Kieran, MD, PhD, director of Pediatric Neuro-Oncology at Dana-Farber Cancer Institute.

About The Mikey Czech Foundation: The Mikey Czech Foundation, Inc. (the "Foundation") is a 501(c)(3) non-profit foundation established by Mikey's family to finance medical research for pediatric brain tumors, including Diffuse Intrinsic Pontine Glioma ("DIPG") pediatric brainstem tumors. DIPG brain stem tumors are extremely rare.  Approximately 150-200 cases per year are reported nationwide, which unfortunately, relegates this form of cancer to "orphan" status within the medical research community, as too few children develop these type of brain tumors to warrant the necessary investment of scarce medical research dollars to find a cure. The Foundation will approve grants to support research at healthcare, education and medical research facilities throughout the United States to assist research in this area.

About Diffuse Intrinsic Pontine Glioma ("DIPG") brain stem tumors affect the cranial nerves, causing symptoms related to the nerves that supply the muscles of the eye and face, and muscles involved in swallowing. These symptoms include double vision, inability to close the eyelids completely, "drooping" on one side of the face, and difficulty chewing and swallowing. The tumor also affects the "long tracks" of the brain, with resultant weakness of the arms or legs and difficulty with speech and walking. As the tumor grows, children initially lose their ability to use their limbs. Thereafter, they sequentially lose control of their bowels, hearing, vision and their ability to swallow and breathe. Notwithstanding their physical deterioration, the children maintain their mental faculties, are fully cognizant of what is happening to them, and experience pain comparable to that of being skinned alive.

Symptoms usually worsen rapidly because the tumor is rapidly growing. The patient's symptoms often improve dramatically during or after six weeks of radiation. Unfortunately, problems usually recur after six to nine months, and progress rapidly. Survival past 12 to 14 months is uncommon, and new approaches to treating these tumors are urgently needed.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs